OakChart

Guardant Health Inc

GHHealthcare·Diagnostics & Research·USA·Large·NASD·Nov 11 • 9:53 AM ET

160.03+4.68 (3.01%)
2026-11-11 15:54 CET
Market cap
21,016.68 USD m
Revenue, TTM
1,278.88 USD m
Net income, TTM
-485.07 USD m
Free cash flow, TTM
-219.96 USD m
EPS diluted, TTM
-3.68
P/E
-
Compare

Price

GH against its 20, 50 and 200-day averages
2050200miss
100.00125.00150.00175.009.4M18.7MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GHclose 160.0320-day 166.7250-day 169.10200-day 132.38160.03

16.2% under 191.05 on 6 Oct 2026. Last 15 sessions, 36.4% high to low

Profile

GH
52-week range, 73% of the way up
74.55191.05

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.

IndexRUI
Employees2506
IPOOct 04, 2018
Beta1.68
ATR, 14d10.02
Rel volume1.07
Short float7.27%
Insider own4.05%
Inst own100.69%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap21.65B
Enterprise Value22.31B
Income-485.07M
Sales1.28B
Book/sh-2.05
Cash/sh7.59
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2506
IPOOct 04, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S16.93
P/B-
P/C21.08
P/FCF-
EV/EBITDA-
EV/Sales17.45
Quick Ratio3.35
Current Ratio3.60
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.68
EPS next Y-2.18
EPS next Q-0.74
EPS this Y-1.93%
EPS next Y35.47%
EPS next 5Y55.28%
EPS past 3/5Y19.67% -4.99%
Sales past 3/5Y29.75% 27.92%
EPS Y/Y TTM-14.59%
Sales Y/Y TTM41.69%
EPS Q/Q-24.52%
Sales Q/Q36.12%
EarningsNov 05 AMC
EPS/Sales Surpr.-23.98% 2.92%

Ownership

Insider Own4.05%
Insider Trans-14.12%
Inst Own100.69%
Inst Trans-0.08%
ROA-30.68%
ROE-
ROIC-34.98%
Gross Margin65.19%
Oper. Margin-39.37%
Profit Margin-37.93%
SMA20-4.01%
SMA50-5.36%
SMA20020.89%
Trades-

Technical

Shs Outstand134.72M
Shs Float129.81M
Short Float7.27%
Short Ratio4.69
Short Interest9.43M
52W High191.05 -16.24%
52W Low74.55 114.66%
Volatility8.22% 6.11%
ATR (14)10.02
RSI (14)45.13
Beta1.68
Rel Volume1.07
Avg Volume2.01M
Volume228,730

Performance

Perf Week-5.07%
Perf Month-1.27%
Perf Quarter0.31%
Perf Half Y62.52%
Perf YTD56.68%
Perf Year63.78%
Perf 3Y641.57%
Perf 5Y52.00%
Perf 10Y-
Recom1.41
Target Price204.75
Prev Close155.35
Price160.03
Change %3.01%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 23, 2026InitiatedRRoth CapitalBuy$200+25.0%
Sep 09, 2026ResumedUUBSBuy$225+40.6%
Sep 08, 2026InitiatedRRothschild & Co RedburnBuy$203+26.9%
Jun 26, 2026ResumedBBernsteinOutperform$175+9.4%
Jun 12, 2026InitiatedRRBC Capital MktsOutperform$185+15.6%
Jun 05, 2026InitiatedGGoldmanBuy$165+3.1%
Jun 02, 2026UpgradeEEvercore ISIIn-line → Outperform$1600.0%
Jun 02, 2026ResumedWWolfe ResearchOutperform$150-6.3%
Feb 20, 2026ReiteratedCCanaccord GenuityBuy$125 → $135-15.6%
Feb 17, 2026InitiatedRRobert W. BairdOutperform$120-25.0%

Peers

Mkt cap
TickerCompanyMkt cap
GRALGRAIL Inc5.77B
NTRANatera Inc46.13B
FRNMFreenome Inc1.21B
TEMTempus AI Inc15.00B
NEONeogenomics Inc2.23B
PSNLPersonalis Inc1.73B
ILMNIllumina Inc33.06B
VCYTVeracyte Inc2.04B
DGXQuest Diagnostics Inc28.54B
ADPTAdaptive Biotechnologies Corp5.12B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
MIGNONE ROBERTODirectorOct 21 '26Option Exercise0.00264010,538Oct 22 04:47 PM
Hidalgo Medina ManuelDirectorOct 17 '26Option Exercise0.0023205,252Oct 19 05:02 PM
Tariq MusaDirectorOct 15 '26Option Exercise0.00250011,699Oct 19 05:02 PM
Tariq MusaDirectorOct 16 '26Sale165.8811619,24211,583Oct 19 05:02 PM
Tariq MusaDirectorOct 16 '26Proposed Sale165.8811619,242Oct 16 04:00 PM
Azar Alex M IIDirectorOct 14 '26Sale159.896911,032893Oct 15 06:02 PM
Azar Alex M IIDirectorOct 14 '26Proposed Sale159.886911,032Oct 14 04:01 PM
Azar Alex M IIDirectorOct 12 '26Option Exercise0.001370962Oct 13 05:10 PM
Saia John G.Chief Legal OfficerOct 01 '26Option Exercise0.007,063046,054Oct 02 05:01 PM
Monroe Terilyn J.Chief People OfficerOct 01 '26Option Exercise0.004,019026,998Oct 02 05:01 PM
Kalia KumudChief Information OfficerOct 01 '26Option Exercise0.006,046045,840Oct 02 05:00 PM
Freeman ChrisChief Commercial OfficerOct 01 '26Option Exercise0.007,416072,790Oct 02 05:00 PM
Chudova DaryaChief Technology OfficerOct 01 '26Option Exercise0.008,033078,668Oct 02 04:59 PM
Bell Michael BrianChief Financial OfficerOct 01 '26Option Exercise0.007,280059,096Oct 02 04:59 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWPiShares Russell Mid-Cap Growth ETFAUM: 18.09B
ARKGARK Genomic Revolution ETFAUM: 1.97B
IWRiShares Russell Mid-Cap ETFAUM: 58.68B
IWFiShares Russell 1000 Growth ETFAUM: 116.57B
VHTVanguard Health Care ETFAUM: 21.51B
SCHMSchwab U.S. Mid-Cap ETFAUM: 15.01B

News

latest 14 of 103
  • Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360 Liquid (Business Wire)
  • PRECISION Study Published in ESMO Open Highlights Utility of Guardant360 Liquid and Guardant Reveal to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases (Business Wire)
  • Guardant Health to Participate in Upcoming Investor Conferences (Business Wire) +5.25%
  • This cancer-testing stock is BTIGs top pick after another major earnings beat (Investing.com)
  • Guardant Health Shares Fall 5.5% as Higher Cash Burn Forecast Overshadows Strong Q3 Revenue Growth (InvestorsHub)
  • Loading…
  • Guardant Health Trails The Whisper By A Penny, But Shield's Surge Powers A Third Revenue Raise As Oncology Pricing Lags Volume (Earnings Whispers) -8.99%
  • Guardant Health falls 12% as cash burn guidance disappoints (Investing.com)
  • Guardant Health: Q3 Earnings Snapshot (Associated Press)
  • It Was Already A Gory Day For Blood-Testing Stocks - Then, Natera And Guardant Reported (Investor's Business Daily)
  • Kevin Sayer Joins Guardant Health Board of Directors (Business Wire)
  • Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test (Business Wire)
  • Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians (Business Wire)
  • Top Specialty Lab Stocks to Watch This Earnings Season, According to BTIG (Investing.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.930-0.750-0.930360.98350.7212
2026Q22026-07-30-0.900-0.762-0.904334.98314.2311
2026Q12026-05-07-0.850-0.806-0.854301.67279.1510
2025Q42026-02-19-1.000-0.767-0.999281.27272.4212
2025Q32025-10-29-0.740-0.790-0.743265.2235.6111
2025Q22025-07-30-0.800-0.741-0.805232.09211.4717
2025Q12025-04-30-0.770-0.760-0.768203.47190.119
2024Q42025-02-20-0.900-0.765-0.897201.81192.1315
2024Q32024-11-06-0.880-0.730-0.876191.48170.4917
2024Q22024-08-07-0.840-0.754-0.838177.24162.5917
2024Q12024-05-09-0.940-0.872-0.945168.49150.0917
2023Q42024-02-22-1.580-0.862-1.578155.05149.618
2023Q32023-11-06-0.730-0.968-0.731143.03137.3514
2023Q22023-08-03-0.670-1.217-0.669137.15129.8515
2023Q12023-05-09-1.300-1.338-1.301128.71117.8715
2022Q42023-02-23-1.360-1.401-1.365126.89123.8214

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.840-0.873-0.835214.38206.24
2020FY-2.600-2.177-2.603286.73284.99
2021FY-4.000-4.260-4.004373.65364.29
2022FY-6.410-6.454-6.406449.54446.54
2023FY-4.280-3.577-4.281563.95558.07
2024FY-3.560-3.413-3.555739.02729.04
2025FY-3.320-3.084-3.320982.02973.05
2026FY--3.384--1,366
2027FY--2.184--1,836
2028FY--0.297--2,524
2029FY-0.621--3,188
2030FY-0.690--3,809

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-092262370.62362.4380.4
2026Q4S2026-11-072261371.01367.2380.4
2026Q4S2026-11-062271371.01367.2380.4
2026Q4S2026-11-052120369.29364.04380.4
2026Q4S2026-10-222120369.29364.04380.4
2026Q4S2026-10-192020369.28364.04380.4
2026Q4S2026-10-162030369.28364.04380.4
2026Q4S2026-10-142030369.28364.04380.4
2026Q4S2026-10-1320170369.28364.04380.4
2026Q4S2026-10-1220170369.28364.04380.4
2026Q4S2026-10-0920161368.26347.3380.4
2026Q4S2026-10-0620161368.24347.3380.4
2026Q4S2026-09-3020161368.25347.3380.4
2026Q4S2026-09-2820171368.39347.3380.4

Estimate history

EPS, annual-1.042-2.798-0.835-2.603-4.004-6.406-4.281-3.555-3.32-3.6819
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.876-0.897-0.768-0.805-0.743-0.999-0.854-0.904-0.925
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual49.84290.639214.375286.73373.653449.538563.948739.016982.0211278.88
Period201720182019202020212022202320242025TTM
Sales, quarterly191.476201.814203.471232.088265.196281.266301.665334.978360.975
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual85.43285.83294.261100.214101.767102.619121.63123.994130.635134.72
Period201720182019202020212022202320242025MRQ
Shares, quarterly123.158123.994123.647124.478125.006130.635131.514133.613134.72
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1,278.88982.02739.02563.95449.54373.65286.73214.3890.64
Cost of Goods Sold Incl. D&A445.18349.01289.80227.05157.87124.2692.5370.7243.21
Gross Profit833.70633.01449.22336.90291.67249.39194.19143.6647.43
Selling, General and Administrative Excl. Other1,337.211,069.31892.81814.91825.44658.01439.44225.60140.37
Research and Development386.67364.19347.75365.09368.61263.22141.3686.2950.71
Other Operating Expense0.000.000.0084.501.100.000.000.000.00
Operating Income-503.51-436.30-443.59-562.51-534.87-408.62-245.25-81.95-92.94
Interest Expense5.223.902.582.582.582.584.771.181.25
Unusual Expense14.105.8544.40-48.45122.34-22.626.780.42-4.25
Net Income Before Taxes-485.90-417.54-435.09-478.76-653.45-384.47-245.90-69.72-84.22
Income Taxes-0.83-1.261.280.691.140.300.38-1.870.04
Consolidated Net Income-485.07-416.28-436.37-479.45-654.59-384.77-246.28-67.85-84.26
Net Income From Continuing Operations-485.07-416.28-436.37-479.45-654.59-405.67-253.78-75.65-85.06
Net Income-485.07-416.28-436.37-479.45-654.59-405.67-253.78-75.65-85.06
EPS (Recurring)-3.54-3.29-3.30-4.58-5.57-4.16-2.55-0.83-2.90
EPS (Basic, Before Extraordinaries)-3.68-3.32-3.56-4.28-6.41-4.00-2.60-0.83-2.80
EPS (Diluted)-3.68-3.32-3.56-4.28-6.41-4.00-2.60-0.83-2.80
EBITDA-464.28-396.56-401.21-519.63-498.91-386.35-229.19-68.34-85.81
Non-Operating Income (Expense)36.9328.5055.4937.886.344.1110.8913.835.72
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense168.33131.31110.9271.7074.80110.56105.2012.385.41
Price To Sales Ratio18.7513.045.075.376.1827.1243.8333.0212.61
Gross Margin65.1964.4660.7959.7464.8866.7467.7367.0152.33
Operating Margin-39.37-44.43-60.02-99.75-118.98-109.36-85.53-38.23-102.54
Net Margin-37.93-42.39-59.05-85.02-145.61-108.57-88.51-35.29-93.85
Shares Outstanding134.72130.64123.99121.63102.62101.77100.2194.2685.83
Market Capitalization21,016.6821,016.683,774.613,283.332,786.2610,167.6312,884.447,337.813,223.49

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue360.98334.98301.67281.27265.20232.09203.47201.81
Cost of Goods Sold Incl. D&A124.82115.95104.9299.4993.5981.2074.7277.59
Gross Profit236.15219.03196.75181.77171.61150.88128.75124.22
Selling, General and Administrative Excl. Other368.92348.15318.10302.05270.60257.30239.79250.19
Research and Development100.8496.5391.0498.2689.9687.4588.5293.54
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-132.76-129.12-121.35-120.27-98.99-106.41-111.04-125.97
Interest Expense1.341.351.351.180.940.980.790.65
Unusual Expense0.000.000.0014.100.000.00-8.67-2.82
Net Income Before Taxes-124.02-119.96-111.70-130.22-92.59-99.86-94.87-110.29
Income Taxes0.340.180.37-1.730.140.040.290.72
Consolidated Net Income-124.36-120.14-112.08-128.49-92.72-99.90-95.16-111.01
Net Income From Continuing Operations-124.36-120.14-112.08-128.49-92.72-99.90-95.16-111.01
Net Income-124.36-120.14-112.08-128.49-92.72-99.90-95.16-111.01
EPS (Recurring)-0.93-0.90-0.85-0.92-0.74-0.80-0.82-0.91
EPS (Basic, Before Extraordinaries)-0.93-0.90-0.85-1.00-0.74-0.80-0.77-0.90
EPS (Diluted)-0.93-0.90-0.85-1.00-0.74-0.80-0.77-0.90
EBITDA-122.59-119.56-111.91-110.22-89.59-96.41-100.81-115.51
Non-Operating Income (Expense)10.0910.5110.995.347.347.548.2913.50
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense49.3245.6037.6135.8033.8233.5429.8328.73
Price To Sales Ratio18.7516.8511.2313.388.647.796.825.12
Gross Margin65.4265.3965.2264.6364.7165.0163.2861.55
Operating Margin-36.78-38.55-40.23-42.76-37.33-45.85-54.57-62.42
Net Margin-34.45-35.87-37.15-45.68-34.96-43.04-46.77-55.00
Shares Outstanding134.72133.61131.51130.64125.01124.48123.65123.99
Market Capitalization21,016.6819,893.9812,116.1713,214.267,791.636,447.135,257.733,774.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,201.60839.981,168.631,011.23932.751,794.88522.80418.96221.32
Short Term Receivables137.85110.2588.7897.2697.6553.3047.9935.6912.79
Inventories85.8871.0861.9551.6030.6722.7215.189.147.29
Other Current Assets40.7233.8027.7431.5153.0517.4711.395.201.54
Total Current Assets1,466.051,055.111,347.111,191.591,114.131,888.36597.36468.99242.94
Net Property, Plant & Equipment304.76279.08302.71341.92313.90100.1272.8131.0016.04
Total Investments and Advances117.71120.310.150.30698.03246.60268.7877.5673.57
Long-Term Note Receivable------1.00--
Intangible Assets103.1810.0512.2715.0217.5019.4918.707.808.74
Other Assets21.9621.05124.1861.1560.9417.213.882.051.66
Total Assets2,013.661,485.611,786.421,609.982,204.502,271.78962.53587.40342.94
Short Term Debt Incl. Current Port. of LT Debt27.6829.2127.9521.8812.866.637.140.100.20
Accounts Payable54.4438.5551.7468.9117.587.3416.2010.645.00
Income Tax Payable----4.224.633.051.470.91
Other Current Liabilities220.61157.82126.23102.43160.0348.2046.3534.7313.53
Total Current Liabilities302.73225.58205.92193.22194.6966.8172.7346.9419.63
Long Term Debt1,682.461,306.841,325.811,347.411,360.87847.8640.147.468.17
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities127.7792.8396.019.183.931.521.678.056.54
Total Liabilities2,112.971,625.261,627.741,549.811,559.49916.19114.5462.4534.33
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00499.97
Common Equity-99.31-139.65158.6860.18645.001,298.49798.39483.15-191.37
Total Shareholders Equity-99.31-139.65158.6860.18645.001,298.49798.39483.15308.61
Accumulated Minority Interest0.000.000.000.000.0057.1049.6041.800.00
Total Equity-99.31-139.65158.6860.18645.001,355.60847.99524.95308.61
Total Liabilities & Stockholders Equity2,013.661,485.611,786.421,609.982,204.502,271.78962.53587.40342.94
Book Value Per Share-0.76-1.131.300.596.3412.968.475.63-2.24
Tangible Book Value Per Share-1.55-1.211.200.446.1712.768.275.54-2.34
Full-Time Employees2,5062,0211,7791,7931,373864622454348
Price to Book Ratio-75.86-62.6113.9616.7115.789.959.236.68-13.21
Return on Assets-23.79-26.67-28.23-34.32-18.13-15.69-9.76-18.29-36.22
Return on Equity--4,584.47-438.13-185.65-41.75-24.21-11.81-21.49-42.86
Return on Invested Capital-26.29-37.39-32.30-46.50-20.22-11.82-9.02-17.34-26.27
Quick Ratio4.564.366.245.905.5727.938.009.8012.01
Current Ratio4.844.686.546.175.7228.278.219.9912.38

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-197.29-416.28-436.37-479.45-654.59-384.77-246.28-67.85-84.26
Depreciation39.2339.7442.3942.8835.9622.2716.0713.617.14
Other Funds (Non Cash)-18.96206.21214.9957.75247.60193.95173.9613.206.07
Funds from Operations-177.02-170.33-179.00-378.81-371.03-168.55-56.26-41.04-71.06
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital15.73-14.43-60.8653.8461.56-40.47-47.66-6.09-1.13
Cash from Operating Activities-161.29-184.76-239.86-324.98-309.46-209.02-103.93-47.13-72.19
Capital Expenditures-58.67-48.31-35.09-20.49-77.46-75.03-54.06-21.29-20.20
Net Assets From Acquisitions-58.99-58.990.000.000.000.000.00-7.33-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.0041.00
Purchase or Sale of Investments-0.00-519.91-279.82859.21227.2811.88-563.03-288.96-132.82
Purchase of Investments-1,068.17-827.23-314.82-635.50-327.72-940.23-1,125.58-614.29-287.45
Sale Or Maturity of Investments1,068.17307.3235.001,494.70555.00952.11562.55325.33154.62
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.0053.601.530.000.000.000.000.00
Cash from Investing Activities-117.66-627.20-261.31840.25149.82-63.16-617.09-317.57-112.03
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock397.71315.1314.84482.5411.9417.86371.22367.74252.60
Repurchase of Common Pref Stock0.00-45.010.000.000.000.000.000.00-0.17
Sale of Common Pref Stock397.71360.1414.84482.5411.9417.86371.22367.74252.78
Proceedsfrom Stock Options330.01327.330.00471.990.000.00354.60349.71252.78
Issuance or Reduction of Debt, Net372.88377.910.000.00-0.07-0.931,132.58-0.44-0.44
Change in Long Term Debt372.88377.910.000.00-0.07-0.931,132.58-0.44-0.44
Issuance of Long Term Debt372.88377.910.000.000.000.001,132.750.000.00
Reduction of Long Term Debt0.000.000.000.00-0.07-0.93-0.17-0.44-0.44
Net Financing Active Other Cash Flow-34.30-21.91-15.83-5.17-200.96-83.76-93.490.000.00
Other Financing Activities Uses-44.15-30.54-15.83-11.20-200.96-83.76-93.490.000.00
Cash from Financing Activities736.29671.13-1.00477.38-189.09-66.821,410.31367.30252.16
Exchange Rate Effect-0.850.49-1.77-0.91-1.60-1.690.460.08-
Net Change in Cash456.49-140.34-503.93991.74-350.34-340.69689.752.6867.95
Free Cash Flow-219.96-233.07-274.94-345.46-386.92-284.05-140.10-65.85-92.39
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,026.851,053.471,102.761,201.60580.01629.14
Short Term Receivables186.55144.25137.40137.85115.58130.25
Inventories93.49105.4683.8585.8890.4984.06
Other Current Assets36.5261.4643.4940.7242.8039.98
Total Current Assets1,343.401,364.641,367.511,466.05828.88883.43
Net Property, Plant & Equipment292.72302.87303.94304.76288.16295.91
Total Investments and Advances125.66120.77118.65117.71129.60122.44
Intangible Assets102.25102.52102.80103.188.779.15
Other Assets21.6221.5022.3921.9621.3721.07
Total Assets1,885.641,912.291,915.292,013.661,276.791,332.00
Short Term Debt Incl. Current Port. of LT Debt28.8027.7628.0327.6826.3926.28
Accounts Payable102.5193.5175.0354.4420.1444.80
Other Current Liabilities241.85217.69189.08220.61190.38167.35
Total Current Liabilities373.17338.96292.14302.73236.92238.43
Long Term Debt1,662.631,669.261,676.531,682.461,299.981,307.87
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities125.75126.94127.69127.7794.3691.17
Total Liabilities2,161.542,135.162,096.362,112.971,631.261,637.47
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-275.90-222.87-181.07-99.31-354.47-305.48
Total Shareholders Equity-275.90-222.87-181.07-99.31-354.47-305.48
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-275.90-222.87-181.07-99.31-354.47-305.48
Total Liabilities & Stockholders Equity1,885.641,912.291,915.292,013.661,276.791,332.00
Book Value Per Share-2.05-1.67-1.38-0.76-2.84-2.45
Tangible Book Value Per Share-2.81-2.44-2.16-1.55-2.91-2.53
Full-Time Employees---2,506--
Price to Book Ratio-75.86-108.97-121.51-36.02-25.46-25.66
Return on Assets-30.68-27.95-26.58-23.79-28.33-28.14
Return on Invested Capital-8.97-8.31-7.49-8.12-9.81-9.97
Quick Ratio3.353.714.394.563.123.35
Current Ratio3.604.034.684.843.503.71

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-124.36-120.14-112.08159.29-380.51-99.90
Depreciation10.189.569.4410.059.4110.04
Other Funds (Non Cash)69.5167.0660.18-215.71338.8349.66
Funds from Operations-44.67-43.52-42.45-46.38-32.27-40.19
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital20.97-14.26-23.2732.29-3.14-20.24
Cash from Operating Activities-23.71-57.78-65.72-14.08-35.41-60.44
Capital Expenditures-13.48-11.76-5.58-27.85-10.35-5.65
Net Assets From Acquisitions0.000.000.00-58.990.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.00113.23705.00-818.23-4.00-5.00
Purchase of Investments0.000.00-249.94-818.23-4.00-5.00
Sale Or Maturity of Investments0.00113.23954.930.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-13.48101.47699.42-905.07-14.35-10.65
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock19.3628.293.65346.413.729.24
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock19.3628.293.65346.413.729.24
Proceedsfrom Stock Options0.0010.360.00319.650.007.68
Issuance or Reduction of Debt, Net0.000.000.00372.880.000.00
Change in Long Term Debt0.000.000.00372.880.000.00
Issuance of Long Term Debt0.000.000.00372.880.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-4.34-5.27-25.130.440.61-7.46
Other Financing Activities Uses-8.40-5.27-25.13-5.35-2.22-7.46
Cash from Financing Activities15.0123.01-21.48719.744.331.77
Exchange Rate Effect0.44-0.41-0.19-0.69-0.530.94
Net Change in Cash-21.7366.30612.02-200.10-45.97-68.37
Free Cash Flow-37.19-69.54-71.31-41.93-45.76-66.08

Revenue breakdown

Biopharma & Data2024: 177.58M 2025: 210.13M
Licensing & Other2024: 13.49M 2025: 8.56M
Oncology2024: 542.83M 2025: 683.60M
Screening2024: 5.12M 2025: 79.73M
Non-US2024: 41.85M 2025: 58.74M
United States2024: 697.16M 2025: 923.28M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.27%9.4M129.8M1.93M
2026-10-159.06%11.7M128.8M1.96M
2026-09-309.25%11.9M128.8M2.13M
2026-09-158.55%11.0M128.8M2.50M
2026-08-318.58%11.1M128.8M2.55M
2026-08-148.69%11.2M128.7M2.68M
2026-07-318.86%11.4M128.8M2.66M
2026-07-158.97%11.4M127.3M2.66M
2026-06-309.54%12.1M127.3M2.58M
2026-06-1510.27%13.1M127.5M2.17M
2026-05-2910.40%13.2M127.0M2.13M
2026-05-1510.18%12.9M127.1M2.02M
2026-04-3010.05%12.8M127.5M2.09M
2026-04-159.23%11.6M126.2M2.04M
2026-03-3110.85%13.7M126.2M2.02M
2026-03-139.08%11.5M126.2M2.00M
2026-02-278.69%11.0M126.2M1.99M
2026-02-138.33%10.5M126.2M2.07M
2026-01-307.62%9.5M124.5M2.29M
2026-01-157.88%9.8M124.5M2.53M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call95.0062.7067.400.002.1940.000.000.990-0.0700.007
call10057.7062.400.002.0120.000.000.989-0.0690.008
call10552.7057.4059.871.8391.000.000.924-0.4400.036
call11048.0052.500.001.6730.000.000.916-0.4360.039
call11543.0047.500.001.5130.000.000.907-0.4310.042
call12038.0042.500.001.3870.000.000.896-0.4300.046
call12533.0037.5035.201.2340.000.000.882-0.4320.050
call13028.1032.5018.301.1092.000.000.862-0.4410.056
call13523.5028.0027.801.0237.000.000.839-0.4440.062
call14019.0023.4023.001.0583.000.000.802-0.4550.071
call14514.5019.007.500.9236.000.000.763-0.4710.078
call15010.7015.0013.000.87947.000.000.712-0.4630.087
call1557.2011.407.500.80033.000.000.641-0.4590.095
call1604.508.508.000.7753100.000.551-0.4470.101
call1652.306.004.800.7511150.000.454-0.4510.101
call1700.804.902.100.8214780.000.371-0.4510.096
call1750.054.101.950.9011460.000.309-0.4510.090
call1800.203.500.650.9561490.000.257-0.4350.082
call1850.303.100.401.0274350.000.222-0.4320.076
call1900.001.300.350.8571100.000.127-0.2510.053
call1950.052.550.300.9503990.000.117-0.2630.050
call2000.002.450.251.0382290.000.109-0.2730.048
call2100.001.350.871.2011550.000.097-0.2910.044
call2200.001.350.201.3511060.000.089-0.3050.041
call2300.000.050.050.89032.000.000.007-0.0240.005
call2400.000.050.010.98235.000.000.006-0.0250.005
call2500.002.150.811.07431.000.000.006-0.0260.004
call2600.002.150.841.15164.000.000.006-0.0260.004
call2700.000.050.201.2639790.000.005-0.0250.004
put95.000.002.150.001.5260.000.00-0.011-0.0590.007
put1000.000.150.251.2618380.00-0.013-0.0530.008
put1050.002.151.822.1525.000.00-0.076-0.4280.036
put1100.002.201.331.95117.000.00-0.085-0.4210.039
put1150.002.250.401.8042610.00-0.093-0.4170.042
put1200.052.350.901.6421310.00-0.105-0.4140.046
put1250.002.501.951.5193620.00-0.118-0.4190.050
put1300.002.751.951.3943,4520.00-0.140-0.4310.057
put1350.053.000.921.26647.000.00-0.161-0.4290.062
put1400.153.501.271.1662,3800.00-0.195-0.4450.070
put1450.204.002.251.06652.000.00-0.237-0.4550.078
put1500.954.804.500.9591,2860.00-0.288-0.4460.087
put1552.606.005.600.8841,6860.00-0.359-0.4410.095
put1604.607.005.600.8052,38955.00-0.449-0.4290.101
put1657.0011.0012.870.8811,1500.00-0.546-0.4330.101
put17010.4014.5022.800.9153550.00-0.629-0.4330.096
put17514.5018.5019.850.9699070.00-0.691-0.4320.090
put18018.9023.0035.900.9947710.00-0.743-0.4150.082
put18523.5027.8034.981.12015.000.00-0.778-0.4110.076
put19028.2032.500.001.1720.000.00-0.873-0.2300.053
put19533.0037.5026.601.2805.000.00-0.883-0.2410.050
put20037.9042.000.001.3820.000.00-0.891-0.2510.048
put21047.8052.0068.401.5720.000.00-0.903-0.2670.044
put22057.8062.000.001.7460.000.00-0.911-0.2810.041
put23067.8072.000.001.9070.000.00-0.9930.0010.005
put24077.8082.500.002.0570.000.00-0.9940.0020.005
put25087.8092.0088.502.1970.000.00-0.9940.0020.004
put26097.8010298.502.3300.000.00-0.9940.0030.004
put270107.8112108.52.4550.000.00-0.9950.0040.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-05SCHEDULE 13GSEC
2026-11-038-KCurrent report2026-11-02SEC
2026-11-038-KCurrent report2026-11-02SEC
2026-10-224Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-17SEC
2026-10-16144Filing for proposed sale of securities under Rule 144.SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-14144Filing for proposed sale of securities under Rule 144.SEC
2026-10-134Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100030.27K2
2026-09003.35M5
2026-080027.33M6
2026-070018.94K1
2026-0678.46K156.43M13
2026-050035.38M9
2026-0400364.99K2
2026-03004.22M4
2026-020000
2026-01002.10M2
2025-120043.69M12
2025-11001.02M3

Institutional holders

Manager% owned
BlackRock, Inc.5.75%
FMR LLC5.47%
PRICE T ROWE ASSOCIATES INC /MD/4.91%
VANGUARD CAPITAL MANAGEMENT LLC4.34%
VANGUARD PORTFOLIO MANAGEMENT LLC4.11%
RATIONAL ADVISORS, INC.4.09%
Invesco Ltd.3.34%
GOLDMAN SACHS GROUP INC2.85%
TWO SIGMA INVESTMENTS, LP2.80%
Capital International Investors2.56%

Funds

Fund% owned
Virtus Income & Growth Fund12.71%
Virtus Convertible Fund12.43%
NYLIM MacKay Convertible Fund12.12%
iShares Convertible Bond ETF9.52%
NYLIM VP MacKay Convertible Portfolio8.44%
Columbia Convertible Securities Fund8.20%
Lord Abbett Convertible Fund5.77%
CALAMOS CONVERTIBLE & HIGH INCOME FUND5.66%
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND5.28%
Calamos Convertible Fund5.28%

OakChart. GH. Cached 15 minutes.